NMRA — Neumora Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Neumora Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed - SEC Filing
Brief: Neumora Therapeutics Initiates Phase 1B Study Of NMRA-511 For Treatment Of Alzheimer’s Disease Agitation
U.S. RESEARCH ROUNDUP- Arista Networks, Crescent Energy, Dell Technologies
Brief: Neumora Therapeutics Announces Initiation Of Phase 2 Study Of Navacaprant In Bipolar Depression
U.S. STOCKS ON THE MOVE-Cisco Systems, Inspired Entertainment, Spirit Airlines
U.S. STOCKS ON THE MOVE-Encore Wire, Masimo, Goldman Sachs
U.S. STOCKS ON THE MOVE-Longeveron, Novavax, Telsa
Neumora Therapeutics falls after US FDA puts schizophrenia drug study on hold
Neumora's early-stage schizophrenia drug study put on hold (updated)
U.S. FDA places clinical hold on Neumora's schizophrenia drug study
U.S. RESEARCH ROUNDUP- Lennar, Republic Services, Ulta Beauty
Brief: Neumora Therapeutics Appoints Kaya Pai Panandiker As Chief Commercial Officer
Brief: Neumora Therapeutics Appoints Jason Duncan As Chief Legal Officer
Brief: Neumora Therapeutics Announces NMRA-266 IND Clearance, Initiation Of Phase 1 Clinical Study
U.S. STOCKS ON THE MOVE-Hyatt Hotels, Walmart, Maxeon
U.S. STOCKS ON THE MOVE-Olema Pharma, Akamai Technologies, US banks
Multiple brokerages start Neumora Therapeutics with bullish rating
Brief: Neumora Therapeutics Announces Appointment Of Robert Lenz As Executive Vice President, Head Of Research And Development
U.S. RESEARCH ROUNDUP-Corning, Juniper Networks, Mirati Therapeutics